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Extracellular vesicles (EV) include vesicles released by either normal or tumor cells. EV may
exceed the nanometric scale (microvesicles), or to be within the nanoscale, also called
exosomes. Thus, it appears that only exosomes and larger vesicles may have the size for
potential applications in nanomedicine, in either disease diagnosis or therapy. This is of
particular interest for research in cancer, also because the vast majority of existing data on
EV are coming from pre-clinical and clinical oncology. We know that the microenvironmen-
tal features of cancer may favor cell-to-cell paracrine communication through EV, but EV
have been purified, characterized, and quantified from plasma of tumor patients as well,
thus suggesting that EV may have a role in promoting and maintaining cancer dissemina-
tion and progression. These observations are prompting research efforts to evaluate the
use of nanovesicles as tumor biomarkers. Moreover, EVs are emerging as natural delivery
systems and in particular, exosomes may represent the ideal natural nanoshuttles for new
and old anti-tumor drugs. However, much is yet to be understood about the role of EV in
oncology and this article aims to discuss the future of EV in cancer on the basis of current
knowledge.
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INTRODUCTION
Extracellular vesicles (EVs) are a mixed population of nanovesi-
cles released by a variety of cells in body fluids, such as plasma,
serum, or urine, of both healthy individuals and cancer patients
(1, 2). EVs are classified based on their size, which ranges from 40
to 10,000 nm, biogenesis and biomarkers. Exosomes (40–100 nm)
originate from the endosomal pathway and they are released by the
cells following the fusion of multivesicular bodies (MVB) with the
plasma membrane. Because of their origin, exosomes are enriched
with scaffolding proteins (tetraspanins), proteins for endosomal
trafficking (ESCRT-related proteins/Alix), and protein chaperons
(heat-shock proteins). Microvesicles and apoptotic bodies (100–
1000 nm) are derived by the outward budding of the plasma
membrane. This mechanism enriches the membrane vesicle with
phospholipids derived from the inner leaflet of the plasma mem-
brane (e.g., phosphatidylserine). The most recently discovered EVs
are large oncosomes (4000–10,000 nm), which derive from bulky
protrusions of cancer cells and they are enriched with scaffold-
ing proteins (e.g., caveolin-1) and tissue-degrading enzymes (e.g.,
metalloproteases). EVs have recently emerged as a promising plat-
form for both diagnostic and therapeutic approaches in personal-
ized cancer medicine. Due to their contents that include specific
proteins, lipids, and nucleic acids, EVs are now considered shuttles
of potential biomarkers for early detection and prognosis of either
primary tumors or metastatic lesions. Additionally, EVs may carry
biomarkers that are usually detected from invasive tissue biopsies,
such as gene mutations for targeted cancer therapies (3). These
findings suggest a new perspective for the management of cancer,
utilizing EVs as a potential source of biomarkers and transitioning
the field to the new concept of “liquid biopsy.” Mechanistically,
EVs may transfer tumor-related molecules into non-tumoral cells
to propagate the disease in both paracrine and systemic manner, or
they may act as disposal systems for unwanted molecules, includ-
ing anti-tumor drugs (4). Growing evidences suggest that these
mechanisms may be exploited to develop new cancer vaccines and
bio-inspired drug delivery systems (5, 6).
This article critically reviews recent reports on the clinical utility
and current limitations of exosomes and microvesicles, generically
defined as EVs, as nanoshuttles of biomarkers, anti-tumor drugs,
and vaccines, opening new avenues for the clinical management
of cancer.
EVs AS SHUTTLES OF TUMOR BIOMARKERS
SCREENING AND EARLY DIAGNOSIS
Biomarkers for cancer screening and diagnosis often display low
sensitivity and/or specificity, missing patients with early stage dis-
ease (false negatives) or detecting those with no disease (false
positives). EVs may offer several potential benefits over current
clinical biomarkers. EVs may shuttle both clinically validated bio-
markers [e.g., prostate-specific antigen (PSA)] and they are a novel
source of proteins and nucleic acids that could be exploited as sur-
rogate biomarkers (7); EVs protect their cargo from the attack of
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nucleases and proteases, increasing biomarker half-life, and poten-
tially facilitating sample integrity and downstream molecular
analyses (8); EVs are well suited for multiplexed biomarker analy-
ses that may increase sensitivity and/or specificity of the diagnostic
assay (8, 9).
Clinical studies for EV-associated cancer biomarkers have been
already described and they are summarized in Table 1. Logozzi
and colleagues performed a retrospective study on EV-associated
biomarkers in stage III and IV melanoma patients and they showed
increased levels of caveolin-1- and CD63-positive EVs in plasma
(2). EV-associated caveolin-1 displayed a sensitivity of 69% and
specificity of 96.3% while levels of serum LDH were altered only in
12.5% of patients (2). Mechanistically, EVs may have a prominent
role in the pathogenesis of melanoma. Melanoma cells have been
shown to release exosome-associated oncoprotein MET to educate
bone marrow progenitor cells and promote metastases in vitro and
in vivo (10), and elevated levels of MET and phospho-MET have
been detected in melanoma patients (10). Additionally, the authors
showed aberrant levels of EV-associated biomarkers TYRP-2,VLA-
4, HSP70, and HSP90 in the plasma of melanoma patients (10).
Indeed,HSPs are emerging as another potential source of EV-based
cancer biomarkers (11). HSP70 is actively secreted by different
types of tumor cells through non-classical protein secretory routes,
including EVs, and HSP70-positive EVs have been shown to acti-
vate macrophages (12) and natural killer cells (13–15) that act
against cancer cells; while, the chaperone HSP90 has been shown
to enhance cancer cell migration when is released by EV-derived
cancer cells (16).
EVs may be exploited as biomarker shuttles for the early diag-
nosis of prostate cancer (PCa). Serum PSA and prostate-specific
membrane antigen (PSMA) have been found on plasma and urine-
derived exosomes, though not validated in a large clinical study
(7, 17). In another report, exosomal survivin was identified as
promising surrogate biomarker for early diagnosis of PCa (19).
Plasma levels of survivin-positive-EVs were higher in PCa patients
than benign hyperplastic patients and healthy donors, potentially
Table 1 | Pre-clinical and clinical studies on EV-shuttled biomarkers.
Cancer biomarker Disease Indication Biofluid Clinical study size Reference
PSA Prostate cancer Screening/early
diagnosis
Urine Controls N =10; disease N =24 (7)
PSA Prostate cancer Screening/early
diagnosis
Plasma Control N =2; disease N =5 (17)
EGFRvIII Glioblastoma Early diagnosis Serum disease N =30 (18)
(phospho)Met Melanoma Early
diagnosis/prognosis
Plasma Controls N =7; stage III N =24;
stage IV N =14
(10)
Caveolin-1 Melanoma Early diagnosis Plasma Controls N =58; disease N =90 (2)
Survivin Prostate cancer Early diagnosis Plasma HD N =8; BPH N =20; disease
N =39
(19)
CD 24 Breast cancer Early diagnosis Serum HD N =14, disease N =18 (20)
EGRF Lung cancer Diagnosis/personalized
medicine
Serum HD N =9; disease N =9 (21)
miR-21, miR-141, miR-200a, miR-200b,
miR-200c, miR-203, miR-205, miR-214
Ovarian cancer Early
diagnosis/prognosis
Serum HD N =10; stage I N =10; stage II
N =10; stage III N =20; stage IV
N =10
(8)
RNU6-1, miR-320, and miR-574-3p Globlastoma Early diagnosis Serum Controls N =50; disease N =50 (22)
TMPRSS2:ERG2 and PCA3 mRNAs Prostate cancer Early diagnosis Urine Blinded prospective study N =30 (23)
let-7a, miR-1229, miR-1246, miR-150,
miR-21, miR-223, and miR-23a
Colorectal cancer Early diagnosis Serum Controls N =22; disease N =88 (23)
miR-151a-5p, miR-30a-3p, miR-200b-5p,
miR-629, miR-100, and miR-154-3p
Lung cancer Early diagnosis Plasma HD N =10; benign disease
N =10; malignant disease N =10
(24)
TGFB1 and MAGE3/6 Ovarian cancer Prognosis/therapy
monitoring
Plasma HD N =10; benign disease
N =10; malignant disease N =22
(25)
TYRP2, HSP70, HSC70, VLA-4 Melanoma Prognosis Plasma HD N =9; stage I N =2; stage III
N =7; stage IV N =18
(10)
miR-21 Human esophageal cell
carcinoma
Prognosis Serum HD=41; disease N =51 (26)
KRAS Pancreatic cancer Personalized medicine Serum HD N =2; disease N =2 (27)
BRAFV600E, EGFR Lung cancer, melanoma Personalized medicine Plasma In vivo model N =8 (3)
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providing an alternative tool to reduce the number of false pos-
itives generated by the PSA test (19). Analysis of the EV cargo
may allow the repositioning of a clinically validated biomarker to
a new diagnostic indication. For example, the FDA has recently
approved a test (commercialized by Hologic) that supports the
clinical decision of repeating a biopsy in suspected PCa patients.
The test is based on QRT-PCR detection of PCA3 mRNA from
urine collected after digital rectal examination (DRE) and it is not
recommended for the early diagnosis of PCa. Instead, a report
from Dijikstra and colleagues suggested that the ratio between the
levels of EV-associated PCA3 and PSA mRNAs might be useful for
the early detection of PCa (9).
EVs have also been evaluated as diagnostic platforms for mul-
tiplexed approaches. Seminal work by Taylor and colleagues iden-
tified the first disease-specific miRNA signature in EVs derived
from ovarian cancer patients (8). They identified a tumor-specific
signature of eight miRNAs in EpCam-positive-EVs that discrimi-
nated ovarian cancer from benign ovarian disease (8). Remarkably,
miRNA levels were not altered by pre-analytical variables such as
collection and storage time (8). In another retrospective study, a
diagnostic signature of miRNAs was found and validated in serum
derived EVs from colorectal cancer patients (23). Sensitivity of the
signature was higher than 90%, while serum biomarkers CEA and
CA19-9 displayed sensitivities of 30.7 and 16%, respectively (23).
These studies provide some level of comfort to support further
research around the clinical use of EVs as biomarkers for screen-
ing and early diagnosis of cancer. However, they suffer from the
lack of standardized protocols of sample collection and storage and
the limited sample size (see Table 1). For the former, some gen-
eral consensus was recently achieved by the International Society
for Extracellular Vesicles (ISEV), though not fully implemented in
clinical studies yet (28). For the latter, large regulated multi-center
clinical studies are needed to validate the use of EVs for potential
diagnostic applications.
CANCER PROGNOSIS AND PERSONALIZED MEDICINE
EV-based diagnostics may be a practical alternative to tumor
biopsy diagnostics that are currently used for prognostic and
“personalized medicine” indications. Indeed, EVs can be collected
with minimally invasive procedures from a variety of body fluids;
they may be more representative of the intra-tumor heterogeneity
than fine needle biopsy, thus potentially revealing aggressive pri-
mary tumor features and distant metastases (25); EVs may allow
the real-time monitoring of therapeutic responses and develop-
ment of resistance mechanisms to targeted therapies where the
mutation status is needed for patient stratification; EVs cargo
may complement the use of other emerging “liquid biopsy” plat-
forms such as circulating tumor DNA or circulating tumor cells
(27). Table 1 summarizes the clinical studies on EV-based bio-
marker for prognosis, monitoring and personalized medicine.
These studies lack the sample size and standard operating pro-
cedures required for clinical validation. However, the established
presence of the disease may facilitate discovery and validation of
cancer-derived biomarkers in these indications. From the regu-
latory perspective, we expect the initial development of EV-based
laboratory developed (LDT) tests, which must meet the regulatory
standard of the clinical laboratory improvement act (CLIA) and
do not require to go through the FDA approval process. Though
the FDA has not approved EV-based tests yet, both industrial
and regulatory entities have expressed their interest in develop-
ing EV-based tests for personalized cancer medicine. There are
several compelling reasons for it. EVs may represent a minimally
invasive platform for the development of companion diagnos-
tic (cDx) tests for targeted therapies. Cancer-derived EVs may
be exploited for the development of blood-based cDx for cetux-
imab (Erbitux) since they carry both the drug target (epidermal
growth factor receptor) and the mutated KRAS gene, which corre-
lates with poor therapeutic responses (21, 27). Cancer-derived EVs
may also shuttle genomic DNA with the mutation BRAFV600E,
which may be used to develop a cDx test to identify melanoma
patients eligible for the treatment with Vemurafenib (3). More-
over, personalized medicine has become one of the fastest grow-
ing segments in the molecular diagnostic market due to FDA’s
recent recommendation of developing cDx tests for approval of
new drugs. From the perspective of diagnostic developers, cDx
tests are very attractive since they may benefit from fast-track
approval and positive clinical adoption. Finally, drug develop-
ers may decide to directly reimburse the cost of cDx test to
drive clinical adoption and sales of the targeted therapy, thus
relieving insurances and patients from a significant economic
burden.
TECHNOLOGICAL CHALLENGES IN THE DEVELOPMENT OF EV-BASED
DIAGNOSTICS
The field of EVs has evolved over the past 5 years especially in
the technical ability to measure genomic and proteomic EV-
associated biomarkers. ELISA-based technologies have been the
gold standard assay for single-plexed detection of low abundant
proteins (down to nanograms per milliliter levels) with high sam-
ple throughput. Conversely, multiplexed technology platforms
based on mass spectrometry (MS) have been employed for pro-
teomic analyses of cancer-derived EVs but offered rather low sam-
ple throughput and detection limits (29). Additionally, the sheer
complexity of a biomolecule samples, such as blood plasma spec-
imen further complicates any proteomic analysis. Typical blood
samples can contain more than 10,000 different protein species,
with concentrations varying over nine orders of magnitude. Such
diversities of proteins, as well as their huge concentration ranges,
present a formidable challenge for sample preparation in pro-
teomics. Conventional protein analysis techniques, based on mul-
tidimensional separation steps and MS, fall short because of the
limited separation peak capacity (up to 3000) and dynamic range
of detection (∼104). Techniques for gene expression analysis have
also their limitations. Microarrays afford high gene density and
potentially high throughput but they are limited in sensitivity and
dynamic range compared to RT-PCR, thus preventing discovery
and analysis of many genes potentially adding power to a cancer
signature.
Currently, there are four technological challenges when work-
ing with EVs: (i) the lack of standardized methods for the isolation
of tumor-derived EVs. Current EV isolation protocols are largely
based on non-specific physical and chemical properties, such as,
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size, density, and solubility as summarized in Table 2. These meth-
ods are inefficient, time consuming and costly, and produce EVs
of variable in yield, purity (origin), and integrity, all features that
make them poorly compatible with routine use for diagnostic pur-
poses; (ii) the need for instrumentation capable of detecting EV
biomarker panels for improved accuracy of patient diagnosis; (iii)
the need for surface chemistry which enables EV biomarker detec-
tion from undiluted blood samples thereby providing maximal
sensitivity; and (iv) the need for low-cost sensor platforms with
high sensitivity and specificity.
EVs AS SHUTTLES OF ANTI-TUMOR DRUGS AND CANCER
VACCINES
Nanobiomedicine seeks to exploit the improved (and often novel)
physical, chemical, and biological properties of materials at the
nanometric scale with a biomimetic approach. EVs may be
exploited as biomimetic nanoshuttles of drugs and cancer vaccines
for several reasons (5, 33). EVs have a key role in many mecha-
nisms promoting cancer development and progression, including
cell–cell communication (34), cell migration (16), metastasis (33),
angiogenesis (18), and drug resistance (5). EVs can either bind
to membrane receptors or directly interact with internal com-
partments of the targeted cell to alter cellular behavior and their
functions (35–38). Selected subpopulations of EVs or exosome-
inspired biomimetic vesicles may be used to deliver anti-tumor
drugs to the tumor site (4, 5). Pre-clinical and clinical studies
showed that inhibition of tumor acidity induces chemosensitiza-
tion in cancer patients (4, 39, 40). Since cancer exosomes act as
disposal system for chemotherapic drugs, pharmacological inhi-
bition of microenvironmental acidity may increase both exosomes
targeting to the tumor site and exosomes uptake by tumor cells, by
simply different electrostatic cargos (4, 39, 40). EVs may medi-
ate gene delivery without inducing adverse immune reactions
since they are amenable to autologous delivery across tissue barri-
ers, including the blood brain barrier (41–43). Furthermore, EVs
may be engineered to carry a variety of biomolecules including
therapeutic RNAs (44–53), small molecules (4, 52, 53), and pro-
tein or peptide ligands (54). Finally, immune cell-derived EVs
may be exploited to develop cancer vaccines. Human natural
killer cell-derived exosomes have shown anti-tumor properties
in vitro and in vivo (54, 55). Dendritic-derived exosomes (Dex)
carry peptide-MHC complexes that can be transferred to recipi-
ent cells and express tumor-derived peptides that induce potent
cytotoxic T lymphocytes (CTL)-mediated responses, leading to
the regression of established tumors in mice (6, 56). Good manu-
facturing laboratory (GMP) procedures for exosome harvesting
and purification have been set up for clinical implementation
(57) and EVs have been approved for use in clinical trials with
the first phase I clinical trial that started at the end of 2000,
30 months after Zitvogel’s group publication (6). In the first clin-
ical study, patients underwent leukapheresis and exosomes were
purified from monocyte derived-DC (MD-DC) in a GMP set-
ting (58). Dex were loaded with MAGE A3 peptides, administered
to 15 stage III/IV melanoma patients through four intradermal
vaccinations at 1 week intervals to promote anti-tumor immu-
nity. This study demonstrated, for the first time, the feasibility
and safety of Dex-based vaccination in melanoma patients (58).
In a similar clinical trial, autologous exosomes were injected
weekly into 13 non-small-cell-carcinoma lung cancer (NSCLC)
patients for 4 weeks but they induced weak immune responses
against the tumor (59). These low immunogenic capacities have
led to the development of second-generation Dex with enhanced
immune-stimulatory properties (60). Viaud et al. reported the
clinical grade manufacture of large-scale interferon-γ-Dex vac-
cines currently used in a phase II trial testing the clinical benefit
of Dex as a maintenance immunotherapy in inoperable (stage
IIIB to IV) NSCLC patients that responded to chemotherapy.
Dex was purified from autologous maturing MD-DC loaded with
MAGE-3 and NY-ESO-1, MAGE-1, MAGE-3, MART-1 restricted
peptides (60). Patients received four cycles of platinum-based
chemotherapy followed by a combination of a 3-week oral ther-
apy with low dose cyclophosphamide followed by four weekly
intradermal Dex injections. The study was launched in Novem-
ber 2009 at the Gustave Roussy and Curie Institutes and the
results are not yet published (60). Another clinical study used
ascites-derived exosomes (Aex) as immunomodulatory agents.
In a phase I clinical trial, Aex were evaluated alone or in com-
bination with the granulocyte-macrophage colony-stimulating
factor (GM-CSF) for the immunotherapy of colorectal cancer
(61). The Aex isolated by sucrose/D(2)O density gradient ultra-
centrifugation contained the diverse immunomodulatory mark-
ers of exosomes and tumor-associated carcinoembryonic anti-
gen (CEA). Both therapies were safe and well tolerated with
mild adverse events (grade 1–2) causally related to the use of
Aex or Aex plus GM-CSF. Importantly, Aex plus GM-CSF but
not Aex alone induced beneficial tumor-specific anti-tumor CTL
responses (61).
Despite these promising results, the use of EVs as shut-
tles of anti-tumor drugs and anti-cancer vaccines is far from
clinical acceptance. The lack of standardized protocols for iso-
lation of clinical grade EVs (sub)populations and the partial
understanding of the mechanisms involving EVs in cancer have
so far hampered the number and the size of these clinical
studies.
Table 2 | Methodologies for the isolation of EVs.
EV isolation method Category EV type Reference
Ultracentrifugation Physico-chemical Total exosome population (18)
Filtration (0.22µm) and ultracentrifugation Physico-chemical Total exosome population (30)
Sucrose gradient Physico-chemical Total exosome population (31)
ExoQuick precipitation Physico-chemical Total EVs population (32)
Immunocapture with magnetic beads with anti-EpCam antibodies Immuno-based EpCam-positive-EVs (8)
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CONCLUSION
Extracellular vesicles have the potential to revolutionize the clin-
ical management of cancer. EVs carry a plethora of validated
and surrogate biomarkers with diagnostic, prognostic, or cDx
value. Among the surrogate biomarkers, molecular chaperones
are likely to yield useful diagnostic and prognostic biomarkers
as well as anti-cancer molecules. Despite the accumulating evi-
dences, most of the clinical studies lack the statistical power
required for biomarker validation and clinical adoption. Fur-
thermore, the biogenesis of EVs during tumorigenesis is largely
unknown, especially in the early phases of the disease. For this
reason, prognosis and therapy follow up may offer a relatively eas-
ier route to biomarker validation than early diagnosis given the
established presence of the disease (or absence in the case of post-
surgery/treatment groups). EVs are also an intriguing source of
biomarkers for personalized medicine. However, they will need to
be evaluated against other “liquid biopsy platforms” such as cir-
culating tumor DNA and circulating tumor cells, which already
have established protocols for isolation from body fluids (62, 63).
Detection of EV-associated biomarkers from plasma or other com-
plex biofluids is still quite challenging since sensitive, multiplexed
assays are not cost effective, robust, and high throughput enough
to drive clinical adoption. Finally, several preliminary studies indi-
cate that autologous EVs as promising delivery systems for drugs
and cancer vaccines due to their ability to target the disease with
only minimal side effects. More studies are warranted to test the
utility of EVs as natural carriers of biomolecules for therapeutic
purposes.
5-YEAR PERSPECTIVES
This new area of nanobiomedicine focuses on multi-disciplinary
research to build new systems for various nanobiomedical appli-
cations, ranging from the medical use of nanoplatform-based
diagnostic agents, to therapeutic agents and even possible future
applications of diagnosis and therapy – theranostics. One of the
most important theranostic strategies is the nanoformulation
of new agents based on an “all in one approach.” In this per-
spective, EVs can be considered potential nanocarriers of both
diagnostic/prognostic biomarkers and therapeutic molecules. In
the next 5 years, we expect that larger multi-center studies will
be performed for the clinical validation of EV as autologous
nanovectors for diagnosis, prognosis, and cancer therapy. Hope-
fully, these efforts will shed some light on the real value of the
clinical use of EVs. We also expect EVs to have an impact in
personalized cancer medicine with the introduction of cheap, mul-
tiplexed, and robust analytical assays and the growing interest of
large pharmaceutical companies, regulatory agencies, and gov-
ernments to reduce patient’s therapeutic burden and healthcare
costs.
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